238 related articles for article (PubMed ID: 31387410)
1. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
Kelly KM; Sanga P; Zaki N; Wang S; Haeussler J; Louie J; Thipphawong J
Curr Med Res Opin; 2019 Dec; 35(12):2117-2127. PubMed ID: 31387410
[No Abstract] [Full Text] [Related]
2. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.
Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
Arthritis Rheumatol; 2017 Apr; 69(4):763-773. PubMed ID: 27748055
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial.
Mayorga AJ; Wang S; Kelly KM; Thipphawong J
Int J Clin Pract; 2016 Jun; 70(6):493-505. PubMed ID: 27238963
[TBL] [Abstract][Full Text] [Related]
4. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.
Sanga P; Polverejan E; Wang S; Kelly KM; Thipphawong J
Clin Ther; 2016 Jun; 38(6):1435-1450. PubMed ID: 27101815
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.
Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
Pain; 2013 Oct; 154(10):1910-1919. PubMed ID: 23748114
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study.
Krupka E; Jiang GL; Jan C
Osteoarthritis Cartilage; 2019 Nov; 27(11):1599-1607. PubMed ID: 31351965
[TBL] [Abstract][Full Text] [Related]
13. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
[TBL] [Abstract][Full Text] [Related]
14. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
15. Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study.
Wang H; Romano G; Fedgchin M; Russell L; Sanga P; Kelly KM; Frustaci ME; Thipphawong J
Clin J Pain; 2017 Feb; 33(2):99-108. PubMed ID: 27153360
[TBL] [Abstract][Full Text] [Related]
16. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
Tiseo PJ; Kivitz AJ; Ervin JE; Ren H; Mellis SJ
Pain; 2014 Jul; 155(7):1245-1252. PubMed ID: 24686255
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
[TBL] [Abstract][Full Text] [Related]
18. Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Slatkin N; Zaki N; Wang S; Louie J; Sanga P; Kelly KM; Thipphawong J
J Pain; 2019 Apr; 20(4):440-452. PubMed ID: 30368018
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
[TBL] [Abstract][Full Text] [Related]
20. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.
Jin Y; Smith C; Monteith D; Brown R; Camporeale A; McNearney TA; Deeg MA; Raddad E; Xiao N; de la Peña A; Kivitz AJ; Schnitzer TJ
Osteoarthritis Cartilage; 2018 Dec; 26(12):1609-1618. PubMed ID: 30240937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
